Alopecia areata

12 trials 1 recruiting MedDRA PT
12 Registered trials
1 Recruiting
5 Unique sponsors
6 Unique IMPs
11 Commercial trials
Drug classes (ATC)
— ATC code not specified 12
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
JAK inhibitor 2 substances
Monoclonal antibody (immune) 1 substance
Phase III: 5 Phase II: 3 Phase I (Other): 4

Filter these 12 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 12 trials

Phase III

5 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    UPADACITINIB
    2023-505061-82-01 13 countries 2024 n=539
    Ended
  • Pfizer Inc. Commercial
    RITLECITINIB TOSILATE
    2023-509801-59-00 4 countries 2020 n=162
    Ended
  • Pfizer Inc. Commercial
    RITLECITINIB TOSILATE
    2024-515438-33-00 5 countries 2026 n=68
    Ended
  • Pfizer Inc. Commercial
    RITLECITINIB TOSILATE
    2024-515439-31-00 5 countries n=78
    Pending
  • Pfizer Inc. Commercial
    RITLECITINIB TOSILATE
    2024-519370-40-00 3 countries 2025 n=74
    Ended

Phase II

3 trials
  • Almirall S.A. Commercial
    LAD603
    2025-523342-27-00 5 countries 2026 n=118
    Recruiting
  • Nektar Therapeutics Commercial
    REZPEGALDESLEUKIN
    2023-509981-39-00 1 country 2024 n=38
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    AMLITELIMAB
    2024-511225-64-00 8 countries 2024 n=74
    Ended

Phase I (Other)

4 trials
  • Pfizer Inc. Commercial
    ETRASIMOD ARGININE
    2023-504411-32-00 1 country 2023 n=16
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2023-505603-23-00 1 country 2024 n=12
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2023-508119-22-00 1 country 2023 n=8
    Ended
  • Pfizer Inc. Academic
    RITLECITINIB TOSILATE
    2022-502872-22-00 1 country 2023 n=12
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Pfizer Inc. Commercial 8 Phase I (Other), Phase III 0
Almirall S.A. Commercial 1 Phase II 1
Nektar Therapeutics Commercial 1 Phase II 0
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase II 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase III 0
New trials by year
2020
1
2023
3
2024
4
2025
1
2026
2
← All indication landscapes